# Supplementary Material

Supplementary Table 1. Studies contributing to evidence base network for the csDMARD-IR monotherapy population

| **Study name** | **Treatment name** | **Treatment code** |
| --- | --- | --- |
| CHANGE29 | Adalimumab 40 mg q2w | Adalimumab mono |
| Placebo | Placebo |
| van de Putte 200430 | Adalimumab 40 mg q2w | Adalimumab mono |
| Placebo | Placebo |
| FAST4WARD31 | Certolizumab 400 mg q4w  | Certolizumab mono |
| Placebo | Placebo |
| Moreland 199932 | Etanercept 25 mg bid qw | Etanercept mono |
| Placebo | Placebo |
| The Etanercept Study 30933, 34 | Etanercept 25 mg bid qw | Etanercept mono |
| Sulfasalazine | csDMARD |
| ADACTA35 | Tocilizumab 8 mg/kg q4w  | Tocilizumab 8 mono |
| Adalimumab 40 mg q2w | Adalimumab mono |
| SATORI36 | Methotrexate | csDMARD |
| Tocilizumab 8 mg/kg q4w | Tocilizumab 8 mono |
| Fleischmann 201219 | Tofacitinib 5 mg bid | Tofacitinib mono |
| Adalimumab 40 mg q2w\*  | Adalimumab mono |
| Placebo | Placebo |
| MONARCH | Sarilumab 200 mg SC q2w | Sarilumab 200 mono |
| Adalimumab 40 mg SC q2w | Adalimumab mono |

bid, twice a day; cs, conventional synthetic; DMARD, disease-modifying antirheumatic drug; IR, inadequate responders or intolerant; mono, monotherapy; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks;
SC, subcutaneous.

\*The adalimumab arm was not included in the networks due to cross-over to tofacitinib at week 12.

Supplementary Table 2. Key features of patient demographics and baseline data for selected studies

|  |
| --- |
| **csDMARD-IR** |
| **Patient demographics** |
| Age | Mean ages were similar between all studies (and study arms), ranging from 50.6 years (Etanercept Study 309) to 56.9 years (CHANGE)  |
| Sex | The majority of patients were female |
| Ethnicity | In those trials reporting ethnicity, the majority of patients were Caucasian; however, in three trials (SATORI, CHANGE and Etanercept Study 309) the entire population was Asian  |
| **Patient baseline clinical status** |
| Weight  | The mean weight varied from 52.4 kg (CHANGE) to 72.8 kg (Etanercept Study 309) |
| Disease duration  | Mean disease duration ranged widely, from 5.6 years (The Etanercept Study 309) to 13.0 years (Moreland 1999)  |
| Tender joint count | Tender joint count ranged from 13.8 (SATORI) to 35.5 (Van De Putte 2004) on the 68-count scale |
| Swollen joint count | Mean swollen joint count ranged from 11.3 (ADACTA) to 25.0 (Moreland 1999) on the 66-count scale |
| Prior DMARD use  | Mean prior DMARD use ranged from 1.5 (Fleischmann 2012) to 3.6 (SATORI) |

cs, conventional synthetic; DMARD, disease-modifying antirheumatic drug; IR, inadequate responders.